Clinical Trial Update: Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of intravenous iron in combination with standard-of-care immunotherapy for melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia
• Melanoma

Drugs mentioned

• Intravenous iron

Snippet

Sponsor: Indiana University | Conditions: Anemia, Iron Deficiency, Melanoma | Phase 2 | Status: WITHDRAWN